Advertisement
Advertisement
CMMB
Chemomab Therapeutics Ltd. - ADR
1.34
USDSponsored
+0.03
+2.67%
Nov 10, 15:59 UTC -5
Closed
After-Market
1.35
0.00
+0.07%
Chemomab Therapeutics Ltd. - ADR (CMMB) Earnings
CMMB Earnings Reports
Positive Surprise Ratio
CMMB beat 4 of 23 last estimates.
17%
Next Report
Date of Next Report
Nov 18, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.11
Implied change from Q2 26 (Revenue/ EPS)
--
/-54.17%
Implied change from Q3 25 (Revenue/ EPS)
--
/--
Chemomab Therapeutics Ltd. - ADR earnings per share and revenue
On Aug 19, 2026, CMMB reported earnings of -0.24 USD per share (EPS) for Q2 26, missing the estimate of -0.15 USD, resulting in a -56.86% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +9.42% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.11 USD, with revenue projected to reach -- USD, implying an decrease of -54.17% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
CalciMedica, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$1.30
Actual
-$0.72
Surprise
+44.64%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
FAQ
What were Chemomab Therapeutics Ltd. - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Chemomab Therapeutics Ltd. - ADR reported EPS of -$0.24, missing estimates by -56.86%, and revenue of $0.00, 0% as expectations.
How did the market react to Chemomab Therapeutics Ltd. - ADR's Q2 2026 earnings?
The stock price moved up 9.42%, changed from $1.91 before the earnings release to $2.09 the day after.
When is Chemomab Therapeutics Ltd. - ADR expected to report next?
The next earning report is scheduled for Nov 18, 2026.
What are the forecasts for Chemomab Therapeutics Ltd. - ADR's next earnings report?
Based on 3
analysts, Chemomab Therapeutics Ltd. - ADR is expected to report EPS of -$0.11 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.